MTNB Matinas BioPharma
- 0.5680
- -0.0130-2.24%
- 0.5403
- -0.0277-4.88%
Matinas BioPharma News
A. G. P. Downgrades Matinas BioPharma(MTNB.US) to Hold Rating
Matinas BioPharma Hldgs Analyst Ratings
Maxim Group Downgrades Matinas BioPharma(MTNB.US) to Hold Rating
Maxim Group Maintains Matinas BioPharma(MTNB.US) With Buy Rating, Maintains Target Price $1
Buy Rating Affirmed: Matinas BioPharma's Solid Financials and Promising Drug Development
Buy Rating Affirmed for Matinas BioPharma on Strong Financials and Promising Oral Antifungal Candidate
BTIG Sticks to Its Buy Rating for Matinas BioPharma (MTNB)
BTIG Keeps Their Buy Rating on Matinas BioPharma (MTNB)
Analysts Offer Insights on Healthcare Companies: Bolt Biotherapeutics (BOLT), Matinas BioPharma (MTNB) and Vor Biopharma (VOR)
Analysts Offer Insights on Healthcare Companies: Athira Pharma (ATHA), Shattuck Labs (STTK) and Matinas BioPharma (MTNB)
BTIG Reiterates Buy on Matinas BioPharma Hldgs, Maintains $3 Price Target
Maxim Group Remains a Buy on Matinas BioPharma (MTNB)
Analysts Offer Insights on Healthcare Companies: Chemed (CHE), Genmab (GMAB) and Matinas BioPharma (MTNB)
Analysts Offer Insights on Healthcare Companies: Matinas BioPharma (MTNB) and Spruce Biosciences (SPRB)
H.C. Wainwright Keeps Their Buy Rating on Matinas BioPharma (MTNB)
Matinas BioPharma Hldgs Analyst Ratings
HC Wainwright & Co. Reiterates Buy on Matinas BioPharma Hldgs, Maintains $3 Price Target
Analysts Are Bullish on Top Healthcare Stocks: Matinas BioPharma (MTNB), Syndax Pharmaceuticals (SNDX)
Analysts Offer Insights on Healthcare Companies: Matinas BioPharma (MTNB) and Talaris Therapeutics (TALS)
Maxim Group Sticks to Their Buy Rating for Matinas BioPharma (MTNB)
No Data